dwinnex.com

UnitedHealth Group Incorporated [NYSE:UNH]: Analyst Rating and Earnings

Equities traders often pay a significant amount of attention to what top market analysts have to say about a potential stock investment. In regards to UnitedHealth Group Incorporated [UNH], the most recent average analyst recommendation we can read comes from the fiscal quarter ending in December. On average, stock market experts give UNH an Outperform rating. Its stock price has been found in the range of 208.07 to 287.94. This is compared to its latest closing price of $236.08.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for UnitedHealth Group Incorporated [UNH] is sitting at 1.58. This is compared to 1 month ago, when its average rating was 1.60.

For the quarter ending in Mar-19 UnitedHealth Group Incorporated [UNH] generated $60.31 billion in sales. That’s 1.00% higher than the average estimate of $59.71 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Keep your eyes on this company’s next financial results, which are scheduled to be made public on Tue 16 Jul (In 61 Days).

Fundamental Analysis of UnitedHealth Group Incorporated [UNH]

Now let’s turn to look at profitability: with a current Operating Margin for UnitedHealth Group Incorporated [UNH] sitting at +7.67, this company’s Net Margin is now 5.50%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is 19.65, and its Return on Invested Capital has reached 15.60%. Its Return on Equity is 24.10, and its Return on Assets is 8.12. These metrics all suggest that UnitedHealth Group Incorporated is doing well at using the money it earns to generate returns.

Turning to investigate this organization’s capital structure, UnitedHealth Group Incorporated [UNH] has generated a Total Debt to Total Equity ratio of 70.71. Similarly, its Total Debt to Total Capital is 41.42, while its Total Debt to Total Assets stands at 23.70. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 66.89, and its Long-Term Debt to Total Capital is 39.19.

What about valuation? This company’s Enterprise Value to EBITDA is 12.86. The Enterprise Value to Sales for this firm is now 1.10, and its Total Debt to Enterprise Value stands at 0.13. UnitedHealth Group Incorporated [UNH] has a Price to Book Ratio of 4.63, a Price to Cash Flow Ratio of 15.58 and P/E Ratio of 18.59. These metrics all suggest that UnitedHealth Group Incorporated is more likely to generate a positive ROI.

Shifting the focus to workforce efficiency, UnitedHealth Group Incorporated [UNH] earns $754,157 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 1.53. This publicly-traded organization’s liquidity data is also interesting: its Current Ratio is 0.64.

UnitedHealth Group Incorporated [UNH] has 958.00M shares outstanding, amounting to a total market cap of $226.16B. Its stock price has been found in the range of 208.07 to 287.94. At its current price, it has moved by -16.82% from its 52-week high, and it has moved 15.11% from its 52-week low.

This stock’s Beta value is currently 0.72, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 51.70. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is UnitedHealth Group Incorporated [UNH] a Reliable Buy?

Shares of UnitedHealth Group Incorporated [UNH], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.